If Apabetalone is successful I doubt if Canakinumab, at a cost of $16,000/month, will be much competition for our target population.9

Thanks for the link to the article Next, it supports other articles I've read that seem to suggest it can take 6 to 12 months to make a deal for a single molecule. Further, I can imagine it would be quite an undertaking to make a deal for RVX as a whole with now FDA approved ph 3 BetOnMace, FDA approval for a ph 2 renal trial and multiple compounds ready for the clinic. Judging by the staged EV chart the company has provided I imagine DM would be asking for a rich deal.